excellent point @dachopper
Our cells work for both paediatric and adult aGVHD and our partner in Japan is saving lives and lifting their bottom line exponentially!
Demonstrating our manufacturing processes are extraordinarily repeatable and consistent in batch potency and effectiveness.
It's only a matter of time before the FDA approve with the supply of additional information as per the CRL, they are just being cautious as it will be the first stem cell approval in the USA and IMO it will be approved and then MSB will have complete rights to maximal profits in a market significantly larger than Japan!
oh! Going Great, page-52
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |